The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and biomarker analysis.
Ahmad A. Tarhini
Consultant or Advisory Role - AstraZeneca; Genentech; Prometheus
Research Funding - Amgen; Bristol-Myers Squibb; Merck; Pfizer; Prometheus
Howard Edington
No relevant relationships to disclose
Lisa H. Butterfield
No relevant relationships to disclose
Yongli Shuai
No relevant relationships to disclose
Yan Lin
No relevant relationships to disclose
Uma N. Rao
No relevant relationships to disclose
John M. Kirkwood
Consultant or Advisory Role - GlaxoSmithKline; Merck; Novartis
Research Funding - Prometheus
Other Remuneration - Amgen; Imedex